Page last updated: 2024-11-06

D-serine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

D-serine is a non-proteinogenic amino acid that acts as a co-agonist at the NMDA receptor, a type of glutamate receptor. It is synthesized from L-serine by the enzyme serine racemase. D-serine plays a critical role in synaptic plasticity, learning, and memory. It is involved in the regulation of neuronal activity, and its levels are altered in several neurological disorders, including schizophrenia, Alzheimer's disease, and stroke. D-serine has been studied extensively for its potential therapeutic applications in these disorders. Research on D-serine aims to understand its role in brain function and its potential for treating neurological diseases.'

Cross-References

ID SourceID
PubMed CID71077
CHEMBL ID285123
CHEBI ID16523
SCHEMBL ID43094

Synonyms (80)

Synonym
ai3-18476
serine d-form
einecs 206-229-4
nsc 77689
(r)-2-amino-3-hydroxypropanoic acid
d-serin
d-ser
CHEBI:16523 ,
DSN ,
(2r)-2-amino-3-hydroxypropanoic acid
(r)-2-amino-3-hydroxy-propionic acid
c3h7no3
bdbm23167
chembl285123 ,
EU-0101088
d-serine, >=98% (tlc)
BPBIO1_001226
serine, d-
BIOMOL-NT_000197
LOPAC0_001088
C00740
D-SERINE ,
312-84-5
(2r)-2-amino-3-hydroxy-propanoic acid
DB03929
1PB8
NCGC00094363-03
NCGC00094363-04
NCGC00094363-01
NCGC00094363-02
S-2590
r(-)-2-amino-3-hydroxypropionic acid
DD977692-169B-4266-88C3-E07F0B21A5BF
S 4250
NCGC00094363-05
(d)-serine
d-2-amino-3-hydroxypropionic acid
S0033
h-d-ser-oh
A20674
d-(+)-serine;d-serine;d-2-amino-3-hydroxypropionic acid; (r)-2-amino-3-hydroxypropionic acid
NCGC00094363-06
HMS3263I18
AKOS006239590
cas-312-84-5
dtxcid7021021
tox21_111269
dtxsid9041021 ,
CCG-205165
(r)-serine
unii-1k77h2z9b1
1k77h2z9b1 ,
AM20090441
LP01088
AKOS015854121
S6224
gtpl4171
(2r)-serine
SCHEMBL43094
serine d-form [mi]
mfcd00004269
NCGC00261773-01
tox21_501088
HB0267
AC-24073
(r)-2-amino-3-hydroxypropionic acid
d-serine / (r)-2-amino-3-hydroxypropanoic acid
CS-D1751
(r)-2-amino-3-hydroxypropanoate
d-serine, vetec(tm) reagent grade, 99%
[3h]-d-serine
HY-100808
Q27077119
13095-79-9
AS-11730
SDCCGSBI-0051058.P002
NCGC00094363-10
NCGC00094363-07
EN300-67234
Z1070067572

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Thus, a potent DAAO inhibitor with a longer half-life should be capable of maintaining high plasma D-serine levels over a sustained period of time and might have therapeutic implications for the treatment of schizophrenia."( Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
Brandon, NJ; Engle, SJ; Jaaro-Peled, H; Rais, R; Rojas, C; Sawa, A; Slusher, BS; Strick, CA; Thomas, AG; Tsukamoto, T; Wozniak, K; Wu, Y, 2012
)
0.9

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
NMDA receptor agonistAn excitatory amino acid agonist which binds to NMDA receptors and triggers a response.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
serine zwitterionAn amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of serine.
D-alpha-amino acid
serineAn alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Amino acid synthesis and interconversion (transamination)2343
Serine biosynthesis416
MECP2 and associated Rett syndrome011

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.35480.100020.879379.4328AID588453; AID588456
TDP1 proteinHomo sapiens (human)Potency2.98550.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency23.91450.000221.22318,912.5098AID743063
regulator of G-protein signaling 4Homo sapiens (human)Potency0.84370.531815.435837.6858AID504845
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.83250.000229.305416,493.5996AID743078
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.98740.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00250.540617.639296.1227AID2364; AID2528
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
lamin isoform A-delta10Homo sapiens (human)Potency12.58930.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency17.78280.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, N-methyl-D-aspartate Receptor Subunit 1Rattus norvegicus (Norway rat)Ki7.02000.540082.8533241.0000AID977610
Chain A, N-methyl-D-aspartate Receptor Subunit 1Rattus norvegicus (Norway rat)Ki7.02000.540082.8533241.0000AID977610
Chain A, N-methyl-D-aspartate Receptor Subunit 1Rattus norvegicus (Norway rat)Ki7.02000.540082.8533241.0000AID977610
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.48500.00071.600310.0000AID143065; AID145260
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)0.30000.00071.630610.0000AID145260
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)0.30000.00061.525710.0000AID145260
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)0.30000.00071.747210.0000AID145260
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)0.30000.00071.741110.0000AID145260
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)0.30000.00071.741110.0000AID145260
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)0.30000.00071.741110.0000AID145260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)EC50 (µMol)0.38670.00301.29038.3000AID144825; AID145252; AID1818527; AID1818528; AID1818529; AID1818530
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)EC50 (µMol)0.45330.00301.02226.8600AID144825; AID145252; AID1818527
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)EC50 (µMol)0.32670.00300.86696.8600AID144825; AID145252; AID1818528
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)EC50 (µMol)0.18330.00301.11276.8600AID144825; AID145252; AID1818529
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)EC50 (µMol)0.17000.00301.39378.3000AID144825; AID145252; AID1818530
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)EC50 (µMol)0.18000.00300.90516.8600AID144825; AID145252
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)EC50 (µMol)0.18000.00300.90516.8600AID144825; AID145252
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
L-cystine transportNeutral amino acid transporter AHomo sapiens (human)
amino acid transportNeutral amino acid transporter AHomo sapiens (human)
glutamine transportNeutral amino acid transporter AHomo sapiens (human)
L-alanine transportNeutral amino acid transporter AHomo sapiens (human)
L-cystine transportNeutral amino acid transporter AHomo sapiens (human)
proline transportNeutral amino acid transporter AHomo sapiens (human)
L-serine transportNeutral amino acid transporter AHomo sapiens (human)
threonine transportNeutral amino acid transporter AHomo sapiens (human)
hydroxyproline transportNeutral amino acid transporter AHomo sapiens (human)
synaptic transmission, glutamatergicNeutral amino acid transporter AHomo sapiens (human)
proline transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
cognitionNeutral amino acid transporter AHomo sapiens (human)
L-aspartate import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
transport across blood-brain barrierNeutral amino acid transporter AHomo sapiens (human)
chloride transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
L-serine import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
L-alanine import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
L-glutamate transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
amino acid transportNeutral amino acid transporter B(0)Homo sapiens (human)
glutamine transportNeutral amino acid transporter B(0)Homo sapiens (human)
glutamine secretionNeutral amino acid transporter B(0)Homo sapiens (human)
neutral amino acid transportNeutral amino acid transporter B(0)Homo sapiens (human)
L-serine transportNeutral amino acid transporter B(0)Homo sapiens (human)
erythrocyte differentiationNeutral amino acid transporter B(0)Homo sapiens (human)
symbiont entry into host cellNeutral amino acid transporter B(0)Homo sapiens (human)
protein homotrimerizationNeutral amino acid transporter B(0)Homo sapiens (human)
L-aspartate import across plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
transport across blood-brain barrierNeutral amino acid transporter B(0)Homo sapiens (human)
L-glutamine import across plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
L-cystine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
chloride channel activityNeutral amino acid transporter AHomo sapiens (human)
amino acid transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-alanine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-aspartate transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-cystine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-glutamine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-proline transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-serine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-threonine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
symporter activityNeutral amino acid transporter AHomo sapiens (human)
L-hydroxyproline transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
virus receptor activityNeutral amino acid transporter B(0)Homo sapiens (human)
protein bindingNeutral amino acid transporter B(0)Homo sapiens (human)
amino acid transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-aspartate transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-glutamine transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-serine transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
symporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
antiporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
ligand-gated channel activityNeutral amino acid transporter B(0)Homo sapiens (human)
signaling receptor activityNeutral amino acid transporter B(0)Homo sapiens (human)
metal ion bindingNeutral amino acid transporter B(0)Homo sapiens (human)
neutral L-amino acid transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneNeutral amino acid transporter AHomo sapiens (human)
centrosomeNeutral amino acid transporter AHomo sapiens (human)
intermediate filamentNeutral amino acid transporter AHomo sapiens (human)
plasma membraneNeutral amino acid transporter AHomo sapiens (human)
cell surfaceNeutral amino acid transporter AHomo sapiens (human)
membraneNeutral amino acid transporter AHomo sapiens (human)
melanosomeNeutral amino acid transporter AHomo sapiens (human)
synapseNeutral amino acid transporter AHomo sapiens (human)
extracellular exosomeNeutral amino acid transporter AHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
basal plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
membraneNeutral amino acid transporter B(0)Homo sapiens (human)
melanosomeNeutral amino acid transporter B(0)Homo sapiens (human)
extracellular exosomeNeutral amino acid transporter B(0)Homo sapiens (human)
plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (69)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1209463AUC (0 to last) in DAAO knockout mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1209458Elimination half life in wild-type mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID144825Compound was evaluated for in vitro inhibition of [3H]TCP at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID1209474Cmax in wild-type mouse at 30 mg/kg, po in presence of CBIO2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1818528Agonist activity at rat GluN1/GluN2B NMDA receptor expressed in Xenopus oocytes measured after 4 days in presence of L-glutamte by two-electrode voltage-clamp recording assay
AID1751483Antibiofilm activity against Staphylococcus aureus assessed as biofilm formation at 100 uM measured by crystal violet staining based microplate reader assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Discovery of non-proteinogenic amino acids inhibiting biofilm formation by S. aureus and methicillin-resistant S. aureus.
AID1209468Drug uptake in wild-type mouse cortex at 30 mg/kg, po after 1 hr2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1209475Cmax in DAAO knockout mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID1209459Elimination half life in wild-type mouse at 30 mg/kg, po in presence of CBIO2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1209460Elimination half life in DAAO knockout mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1818530Agonist activity at rat GluN1/GluN2D NMDA receptor expressed in Xenopus oocytes measured after 4 days in presence of L-glutamte by two-electrode voltage-clamp recording assay
AID1209467Drug uptake in DAAO knockout mouse cerebellum at 30 mg/kg, po after 1 hr2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1209470Tmax in wild-type mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1209466Drug uptake in wild-type mouse cerebellum at 30 mg/kg, po after 1 hr2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID146062Effective concentration against NR1/NR2C receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID145252In vitro concentration eliciting half-maximal effect on [3H]-MK 801 radioligand binding to NMDA receptor1999Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10
Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands.
AID146060Effective concentration against NR1/NR2B receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID146064Effective concentration against NR1/NR2D receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID1818527Agonist activity at rat GluN1/GluN2A NMDA receptor expressed in Xenopus oocytes measured after 4 days in presence of L-glutamte by two-electrode voltage-clamp recording assay
AID1209471Tmax in wild-type mouse at 30 mg/kg, po in presence of CBIO2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID430782Displacement of [3H]glycine from strychnine-insensitive glycine recognition site of NMDA receptor in rat brain cortex membrane2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
AID1818531Agonist activity at rat GluN1/GluN2A NMDA receptor expressed in Xenopus oocytes assessed as maximal relative efficacy measured after 4 days in presence of L-glutamte by two-electrode voltage-clamp recording assay relative to glycine
AID1209469Drug uptake in DAAO knockout mouse cortex at 30 mg/kg, po after 1 hr2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID145253In vitro maximal effect on [3H]-MK 801 binding to NMDA receptor as compared to a basal value of 100%1999Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10
Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands.
AID1818543Agonist activity at rat GluN1/GluN2B NMDA receptor expressed in Xenopus oocytes assessed as maximal relative efficacy measured after 4 days in presence of L-glutamte by two-electrode voltage-clamp recording assay relative to glycine
AID1209465AUC (0 to infinity) in wild-type mouse at 30 mg/kg, po in presence of CBIO2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1209462AUC (0 to last) in wild-type mouse at 30 mg/kg, po in presence of CBIO2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1209472Tmax in DAAO knockout mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID143065In vitro inhibitory activity to inhibit [3H]glycine binding to NMDA receptor1999Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10
Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands.
AID1209464AUC (0 to infinity) in wild-type mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1751482Antibacterial activity in Staphylococcus aureus assessed as bacterial growth rate at 100 uM measured by UV absorbance based analysis2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Discovery of non-proteinogenic amino acids inhibiting biofilm formation by S. aureus and methicillin-resistant S. aureus.
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID1209461AUC (0 to last) in wild-type mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID1818539Agonist activity at rat GluN1/GluN2D NMDA receptor expressed in Xenopus oocytes assessed as maximal relative efficacy measured after 4 days in presence of L-glutamte by two-electrode voltage-clamp recording assay relative to glycine
AID1818529Agonist activity at rat GluN1/GluN2C NMDA receptor expressed in Xenopus oocytes measured after 4 days in presence of L-glutamte by two-electrode voltage-clamp recording assay
AID146058Effective concentration against NR1/NR2A receptor2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID1818538Agonist activity at rat GluN1/GluN2C NMDA receptor expressed in Xenopus oocytes assessed as maximal relative efficacy measured after 4 days in presence of L-glutamte by two-electrode voltage-clamp recording assay relative to glycine
AID1209473Cmax in wild-type mouse at 30 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
AID145260In vitro inhibition of [3H]glycine at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1811Experimentally measured binding affinity data derived from PDB2003The EMBO journal, Jun-16, Volume: 22, Issue:12
Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2003The EMBO journal, Jun-16, Volume: 22, Issue:12
Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (7.41)18.2507
2000's6 (22.22)29.6817
2010's10 (37.04)24.3611
2020's9 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.58 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index73.28 (26.88)
Search Engine Supply Index3.84 (0.95)

This Compound (31.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]